Thelansis

 Ependymomas are tumors originating from glial cells. They predominantly develop within the lining of the ventricular system but less frequently outside the central nervous system (CNS) or within the brain tissue. They exhibit distinct genetic subgroups and are more prevalent in children than adults. Based on genetic mutations and variations, ependymomas are categorized as follows:   Posterior fossa (PF):   ·        PF-EPN-SE (subependymoma) ·        PF-EPN-B (group B) ·        PF-EPN-A (group A) Supratentorial (ST):   ·        ST-EPN-SE (subependymoma) ·        ST-EPN-YAP1 (YAP1 fusions) ·        ST-EPN-RELA (RELA fusions) Spinal ependymomas:   ·        SP-EPN-MPE (myxopapillary) ·        SP-EPN-...

  Ependymoma is a rare type of tumor of the brain or spinal cord. It can happen in both children and adults. In children, these tumors tend to be in the brain. In adults, they're often in the spinal cord. These tumors have an incident rate of 0.43 patients per 100 000 population in the United States, accounting for 1.8% of all primary brain tumors. Thelansis’s “Ependymoma Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ependymoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Ependymoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insi...